U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2CH5N3.CH2O3
Molecular Weight 180.1659
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GUANIDINE CARBONATE

SMILES

C(=N)(N)N.C(=N)(N)N.C(=O)(O)O

InChI

InChIKey=STIAPHVBRDNOAJ-UHFFFAOYSA-N
InChI=1S/2CH5N3.CH2O3/c3*2-1(3)4/h2*(H5,2,3,4);(H2,2,3,4)

HIDE SMILES / InChI

Molecular Formula CH2O3
Molecular Weight 62.0248
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula CH5N3
Molecular Weight 59.0705
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Guanidine is a small basic compound. Guanidine stimulates the neuromuscular junction presynaptically by inhibiting voltage-gated potassium (Kv) channels, leading to the enhanced release of acetylcholine in the synaptic cleft. This stimulatory effect of guanidine underlies its use in the therapy for the neuromuscular diseases. The hydrochloride salt of guanidine was approved by FDA for the reduction of the symptoms of muscle weakness and easy fatigability associated with the myasthenic syndrome of Eaton-Lambert.

CNS Activity

Curator's Comment:: The study was performed on rats.

Originator

Curator's Comment:: Original article: A. Strecker, Liebigs Ann. Chem. 1861, 118, 151-177.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
GUANIDINE HYDROCHLORIDE

Approved Use

Guanidine is indicated for the reduction of the symptoms of muscle weakness and easy fatigability associated with the myasthenic syndrome of Eaton-Lambert. It is not indicated for treating myasthenia gravis. The Eaton-Lambert syndrome is ordinarily differentiated from myasthenia gravis by the usual association of the syndrome with small cell carcinoma of the lung, but myography may be necessary to make the diagnosis.

Launch Date

-9.5463362E11
PubMed

PubMed

TitleDatePubMed
Topological diversity of artificial beta-barrels in water.
2001
Expression and refolding of full-length human TIMP-1.
2001
Evolution and physiological roles of phosphagen systems.
2001
Strain-specified relative conformational stability of the scrapie prion protein.
2001 Apr
High-sensitivity fluorescence anisotropy detection of protein-folding events: application to alpha-lactalbumin.
2001 Apr
Synthesis and biological activity of analogues of the antidiabetic/antiobesity agent 3-guanidinopropionic acid: discovery of a novel aminoguanidinoacetic acid antidiabetic agent.
2001 Apr 12
Structure--function relationships in bovine thymus 20S proteasome: a fluorimetric study.
2001 Apr 12
Second-site revertants of a low-sodium-affinity mutant of the Na+/H+ exchanger reveal the participation of TM4 into a highly constrained sodium-binding site.
2001 Apr 24
Probing copper ligands in denatured Pseudomonas aeruginosa azurin: unfolding His117Gly and His46Gly mutants.
2001 Feb
Human recombinant interferon-inducible protein-10: intact disulfide bridges are not required for inhibition of hematopoietic progenitors and chemotaxis of T lymphocytes and monocytes.
2001 Feb
[Discovery of cis-preference of aromatic N-methylamides and its application to molecular constructions].
2001 Feb
Erythrocyte transketolase activity and guanidino compounds in hemodialysis patients.
2001 Feb
Role of nitric oxide in the synthesis of guanidinosuccinic acid, an activator of the N-methyl-D-aspartate receptor.
2001 Feb
Uremic concentrations of guanidino compounds inhibit neutrophil superoxide production.
2001 Feb
Endogenous guanidino compounds as uremic neurotoxins.
2001 Feb
Specific neosaxitoxin interactions with the Na+ channel outer vestibule determined by mutant cycle analysis.
2001 Feb
Apparent two-state tendamistat folding is a sequential process along a defined route.
2001 Feb 16
Spontaneous and flow-induced Ca2+ transients in retracted regions in endothelial cells.
2001 Feb 16
The folding nucleus of a fibronectin type III domain is composed of core residues of the immunoglobulin-like fold.
2001 Feb 2
Rate of intrachain contact formation in an unfolded protein: temperature and denaturant effects.
2001 Feb 2
Uracil moiety is required for toxicity of the cyanobacterial hepatotoxin cylindrospermopsin.
2001 Feb 23
Efficient gene transfection by bisguanylated diacetylene lipid formulations.
2001 Feb 23
Collision-induced dissociation of ring-opened cyclic depsipeptides with a guanidino group by electrospray ionization/ion trap mass spectrometry.
2001 Jan
Dichlorobis(glycocyamine-O)copper(II).
2001 Jan
Phaeochromocytoma: an unusual cause of hypertension in pregnancy.
2001 Jan
Detection of enterovirus and hepatitis A virus RNA in mussels (Mytilus spp.) by reverse transcriptase-polymerase chain reaction.
2001 Jan
Cellular responses of NG108-15 and SK-N-MC lines to sweet and bitter tastants as measured by extracellular acidification rates.
2001 Jan 1
Limited tryptic hydrolysis of pea legumin: molecular mass and conformational stability of legumin-T.
2001 Jan 10
The influence of ATP on the association and unfolding of the tyrosine repressor ligand response domain of Haemophilus influenzae.
2001 Jan 12
Surprisingly high stability of barley lipid transfer protein, LTP1, towards denaturant, heat and proteases.
2001 Jan 19
Achieving stability and conformational specificity in designed proteins via binary patterning.
2001 Jan 19
A kinetic folding intermediate probed by native state hydrogen exchange.
2001 Jan 19
Engineering conformational flexibility in the lactose permease of Escherichia coli: use of glycine-scanning mutagenesis to rescue mutant Glu325-->Asp.
2001 Jan 23
[Y97V substitution in the horse cytochrome c causes accumulation of the equilibrium intermediate].
2001 Jan-Feb
[Antibody avidity: use for the diagnosis of HIV early infection].
2001 Jan-Feb
A rigid linker-scaffold for solid-phase synthesis of dimeric pharmacophores.
2001 Jan-Feb
Elucidation of a [4Fe-4S] cluster degradation pathway: rapid kinetic studies of the degradation of Chromatium vinosum HiPIP.
2001 Mar
Structure-activity relationship of the p55 TNF receptor death domain and its lymphoproliferation mutants.
2001 Mar
Probing conformational changes in the estrogen receptor: evidence for a partially unfolded intermediate facilitating ligand binding and release.
2001 Mar
Cutinase unfolding and stabilization by trehalose and mannosylglycerate.
2001 Mar 1
Major differences in stability and dimerization properties of two chimeric mutants of human stefins.
2001 Mar 1
The synthesis of beta-peptides containing guanidino groups.
2001 Mar 12
The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin.
2001 Mar 15
Matrix proteins from insect pliable cuticles: are they flexible and easily deformed?
2001 Mar 15
Structural alterations and inhibition of unisite and multisite ATP hydrolysis in soluble mitochondrial F1 by guanidinium chloride.
2001 Mar 20
Probing local conformational changes during equilibrium unfolding of firefly luciferase: fluorescence and circular dichroism studies of single tryptophan mutants.
2001 Mar 23
Dramatic stabilization of an SH3 domain by a single substitution: roles of the folded and unfolded states.
2001 Mar 30
The pro domain of beta-secretase does not confer strict zymogen-like properties but does assist proper folding of the protease domain.
2001 Mar 30
Proton and metal ion-dependent assembly of a model diiron protein.
2001 May
Guanidino-containing drugs in cancer chemotherapy: biochemical and clinical pharmacology.
2001 May 15
Patents

Sample Use Guides

Initial dosage is usually between 10 and 15 mg/kg (5 to 7 mg/pound) of body weight per day in 3 or 4 divided doses. This dosage may be gradually increased to a total daily dosage of 35 mg/kg (16 mg/pound) of body weight per day or up to the development of side effects.
Route of Administration: Oral
In Vitro Use Guide
Mice spinal cord neurons were treated with guanidine at concentrations between 100 nM and 100 mM. At 100 mM induced a membrane depolarization of 10 to 25 mV and rapidly and reversibly reduced GABA responses: 23.9% decrease of GABA responses was obtained with 10 mM guanidine and complete inhibition was observed with 100 mM). It also significantly reduced Glycine response at 10 mM.
Substance Class Chemical
Created
by admin
on Sat Jun 26 03:05:50 UTC 2021
Edited
by admin
on Sat Jun 26 03:05:50 UTC 2021
Record UNII
V3394X3G2W
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GUANIDINE CARBONATE
INCI  
INCI  
Official Name English
NSC-2171
Code English
GUANIDINE CARBONATE [INCI]
Common Name English
CARBONIC ACID, COMPD. WITH GUANIDINE (1:2)
Common Name English
DIGUANIDINIUM CARBONATE
Systematic Name English
GUANIDINE CARBONATE (2:1)
Systematic Name English
BISGUANIDINIUM CARBONATE
Systematic Name English
GUANIDINIUM CARBONATE
Systematic Name English
Code System Code Type Description
ECHA (EC/EINECS)
209-813-7
Created by admin on Sat Jun 26 03:05:50 UTC 2021 , Edited by admin on Sat Jun 26 03:05:50 UTC 2021
PRIMARY
PUBCHEM
11650
Created by admin on Sat Jun 26 03:05:50 UTC 2021 , Edited by admin on Sat Jun 26 03:05:50 UTC 2021
PRIMARY
CAS
593-85-1
Created by admin on Sat Jun 26 03:05:50 UTC 2021 , Edited by admin on Sat Jun 26 03:05:50 UTC 2021
PRIMARY
EPA CompTox
593-85-1
Created by admin on Sat Jun 26 03:05:50 UTC 2021 , Edited by admin on Sat Jun 26 03:05:50 UTC 2021
PRIMARY
FDA UNII
V3394X3G2W
Created by admin on Sat Jun 26 03:05:50 UTC 2021 , Edited by admin on Sat Jun 26 03:05:50 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY